Skip to main
SHC

Sotera Health (SHC) Stock Forecast & Price Target

Sotera Health (SHC) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Sotera Health Co is projected to experience significant financial growth, with adjusted EBITDA expected to increase at a compound annual growth rate of 6.7% from $589 million in 2025 to $716 million in 2028, reflecting a margin expansion from 50.8% to 51.7%. The company anticipates adjusted gross profit growth at a 6.4% compound annual rate, rising from $657 million in 2025 to $791 million in 2028, supported by a steady increase in adjusted gross margins. Additionally, Sotera's strategic focus on expanding its higher-margin lab testing services within Nelson Labs, along with a successful cross-selling strategy, further bolsters its positive outlook in an evolving market landscape.

Bears say

Sotera Health has experienced a significant decline in its adjusted EBITDA margin, decreasing from 51.7% in 2021 to 49.9% in 2024, primarily attributed to inflationary pressures, overstaffing, and unfavorable performance in its Nelson Labs segment. The company is facing challenges from the loss of higher-margin COVID-related personal protective equipment testing volumes, which has negatively impacted profitability and is expected to result in a mid-single-digit decline in sales for Nelson Labs in 2025. Additionally, despite achieving nearly 9.0% organic revenue growth from 2021 to 2022, recent performance has been hampered by supply chain issues such as inventory de-stocking, leading to a negative outlook for the stock.

Sotera Health (SHC) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sotera Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sotera Health (SHC) Forecast

Analysts have given Sotera Health (SHC) a Buy based on their latest research and market trends.

According to 5 analysts, Sotera Health (SHC) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sotera Health (SHC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.